- Coordinator
- Norges Teknisk-Naturvitenskapelige Universitet NTNU, Norway
- Runs
- 1 September 2026 to 31 August 2030
- Status
- Running
- EU funding
- €6.0m
- Total cost
- €6.3m
- Partners
- 12 organisations in 9 countries
- Type
- Innovation Action
- Grant agreement
- 101291450
What the project is doing
In the project's own words, from its summary on CORDIS.
AIMARIA delivers a digital-to-pilot pipeline to unlock the vast but underexploited biosynthetic capacity of marine microbiomes. The project combines AI-driven prioritisation, digital twins, and AI-powered predictive DNA design with advanced synthetic biology, cell-free systems, and engineered novel and established microbial chassis. Through this integrated approach, AIMARIA will deliver sustainable and scalable access to high-value marine natural products, including stalled oncology candidates, such as Peloruside A and Pateamine A, and discover first-in-class bioactive compounds and enzymes.
By demonstrating TRL 6–7 production routes, embedding life cycle and techno-economic assessments, and ensuring compliance with international biodiversity frameworks (Nagoya, KM-GBF, BBNJ), AIMARIA directly supports the EU Bioeconomy Strategy and its objectives to develop sustainable, circular bio-based solutions. The project will strengthen Europe’s leadership in blue biotechnology, accelerate innovation across multiple industrial sectors, and support the objectives of the EU Green Deal and Mission “Restore our Ocean and Waters"".""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Norges Teknisk-Naturvitenskapelige Universitet NTNU | Trondheim | Norway | Coordinator |
| Vib Vzw | Zwijnaarde - Gent | Belgium | Participant |
| Eidgenoessische Technische Hochschule Zuerich | Zuerich | Switzerland | Participant |
| Helmholtz-Zentrum Fur Infektionsforschung GmbH | Braunschweig | Germany | Participant |
| Leibniz-Institut Dsmz-Deutsche Sammlung Von Mikroorganismen Und Zellkulturen GmbH | Braunschweig | Germany | Participant |
| Algorithmiq Oy | Helsinki | Finland | Participant |
| Wageningen University | Wageningen | Netherlands | Participant |
| Syngens AS | Heimdal | Norway | Participant |
| The Research Trust of Victoria University of Wellington | Wellington | New Zealand | Participant |
| Astrazeneca AB | Sodertaelje | Sweden | Associatedpartner |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Participant |
| Prozomix Limited | Haltwhistle | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI